摘要
目的 比较伏诺拉生与艾司奥美拉唑在幽门螺杆菌(Hp)补救治疗中的疗效与安全性。方法 回顾性纳入2020年至2024年昆山市第一人民医院接受Hp补救治疗的140例患者,分为艾司奥美拉唑组(A组,n=69)和伏诺拉生组(B组,n=71)。比较两组的Hp根除率及不良事件发生率。结果 B组根除率为85.9%,高于A组的78.3%,但差异无统计学意义(P=0.237)。多因素逻辑回归分析显示,在调整性别、年龄、抗菌药物方案及既往治疗失败次数后,B组与根除成功显著相关(OR=3.81,95%CI:1.19~12.19,P=0.024 4)。亚组分析提示该关联在男性及既往失败> 1次的患者中更为显著。B组不良事件发生率为8.5%,低于A组的14.5%,差异无统计学意义(P=0.261)。结论 在Hp补救治疗中,伏诺拉生的疗效不劣于艾司奥美拉唑,且安全性相似,在特定临床亚组中可能更具优势。
Objective This study aims to compare the efficacy and safety of vonoprazan versus esomeprazole in the rescue therapy for Helicobacter pylori(Hp)infection.Methods A total of 140 patients from Kunshan First People's Hospital in the rescue therapy for Hp infection between 2020 and 2024 were retrospectively enrolled and divided into two groups:the esomeprazole group(Group A,n=69)and the vonoprazan group(Group B,n=71).The Hp eradication rates and incidence of adverse events were compared between the two groups.Results The eradication rate was 85.9%in Group B and 78.3%in Group A,with no statistically significant difference(P=0.237).However,after adjusting for gender,age,antibiotic regimen,and prior treatment failure,multivariable logistic regression showed that vonoprazan was significantly associated with eradication success(OR=3.81,95%CI:1.19-12.19,P=0.0244).Subgroup analyses further indicated that this association was more pronounced in male patients and those with more than one prior treatment failure.The incidence of adverse events was 8.5%in Group B and 14.5%in Group A,with no significant between-group difference(P=0.261).Conclusion In Hp rescue therapy,vonoprazan is non-inferior to esomeprazole in terms of efficacy and shows a comparable safety profile,with potential advantages in specific clinical subgroups.
作者
戴娜
吴文娟
赵玉琴
沈正林
王梦瑶
朱丽婷
王岚
王庆华
DAI Na;WU Wenjuan;ZHAO Yuqin(Department of Gastroenterology,Kunshan First People's Hospital,Suzhou 215300,China;不详)
出处
《中国处方药》
2025年第24期84-89,共6页
Journal of China Prescription Drug
基金
昆山市第一人民医院2021年科技计划项目(KRY-YN001)。
